Department of Cardiology, Ashford and St Peter's Hospitals NHS Foundation Trust, Guildford Road, Chertsey, Surrey, KT16 0PZ, UK.
School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK.
Intern Emerg Med. 2022 Oct;17(7):1891-1897. doi: 10.1007/s11739-022-03015-8. Epub 2022 Jun 22.
Risk factors for COVID-19-related outcomes have been variably reported. We used the standardised LACE index to examine admissions and in-hospital mortality associated with COVID-19. Data were collected in the pre-pandemic period (01-04-2019 to 29-02-2020) from 10,173 patients (47.7% men: mean age ± standard deviation = 68.3 years ± 20.0) and in the pandemic period (01-03-2019 to 31-03-2021) from 12,434 patients. With the latter, 10,982 were without COVID-19 (47.4% men: mean age = 68.3 years ± 19.6) and 1452 with COVID-19 (58.5% men: mean age = 67.0 years ± 18.4). Admissions and mortality were compared between pre-pandemic and pandemic patients, according to LACE index. Admission rates rose disproportionately with higher LACE indices amongst the COVID-19 group. Mortality rates amongst the pre-pandemic, pandemic non-COVID-19 and COVID-19 groups with LACE index scores < 4 were 0.7%, 0.5%, 0%; for scores 4-9 were 5.0%, 3.7%, 8.9%; and for scores ≥ 10 were: 24.2%, 20.4%, 43.4%, respectively. The area under the curve receiver operating characteristic for predicting mortality by LACE index was 76% for COVID-19 and 77% for all non-COVID-19 patients. The risk of age and sex-adjusted mortality did not differ from the pre-pandemic group for COVID-19 patients with LACE index scores < 4. However, risk increased drastically for scores from 4 to 9: odds ratio = 3.74 (95% confidence interval = 2.63-5.32), and for scores ≥ 10: odds ratio = 4.02 (95% confidence interval = 3.38-4.77). In conclusion, patients with LACE index scores ≥ 4 have disproportionally greater risk of COVID-19 hospital admissions and deaths, in support of previous studies in patients without COVID-19. However, of importance, our data also emphasise their increased risk in patients with COVID-19. Because the LACE index has a good predictive power of mortality, it should be considered for routine use to identify high-risk COVID-19 patients.
与 COVID-19 相关的结局的风险因素有不同的报道。我们使用标准化的 LACE 指数来检查与 COVID-19 相关的入院和住院死亡率。数据收集于大流行前时期(2019 年 1 月 4 日至 2 月 29 日)的 10173 名患者(47.7%为男性:平均年龄±标准差=68.3±20.0 岁)和大流行时期(2019 年 3 月 1 日至 2021 年 3 月 31 日)的 12434 名患者。对于后者,有 10982 名患者没有 COVID-19(47.4%为男性:平均年龄=68.3 岁±19.6 岁)和 1452 名 COVID-19 患者(58.5%为男性:平均年龄=67.0 岁±18.4 岁)。根据 LACE 指数,比较了大流行前和大流行时期患者的入院率和死亡率。在 COVID-19 组中,随着 LACE 指数的升高,入院率不成比例地增加。LACE 指数评分<4 的大流行前、大流行非 COVID-19 和 COVID-19 组的死亡率分别为 0.7%、0.5%和 0%;评分 4-9 的死亡率分别为 5.0%、3.7%和 8.9%;评分≥10 的死亡率分别为 24.2%、20.4%和 43.4%。LACE 指数预测死亡率的曲线下面积接收者操作特征在 COVID-19 患者中为 76%,在所有非 COVID-19 患者中为 77%。COVID-19 患者的年龄和性别调整后死亡率与 LACE 指数评分<4 的大流行前组没有差异。然而,对于评分 4-9 的患者,风险急剧增加:比值比=3.74(95%置信区间=2.63-5.32),对于评分≥10 的患者,比值比=4.02(95%置信区间=3.38-4.77)。总之,LACE 指数评分≥4 的患者 COVID-19 住院和死亡的风险不成比例地增加,这支持了之前在没有 COVID-19 的患者中的研究。然而,重要的是,我们的数据还强调了他们在 COVID-19 患者中的风险增加。由于 LACE 指数对死亡率有很好的预测能力,因此应考虑将其常规用于识别高危 COVID-19 患者。